
CAMP Valuation
CAMP4 Therapeutics Corp
- Overview
- Forecast
- Valuation
- Earnings
CAMP Relative Valuation
CAMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CAMP is overvalued; if below, it's undervalued.
Historical Valuation
CAMP4 Therapeutics Corp (CAMP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 9.38. The fair price of CAMP4 Therapeutics Corp (CAMP) is between 1399.65 to 3984.47 according to relative valuation methord. Compared to the current price of 1.74 USD , CAMP4 Therapeutics Corp is Undervalued By 99.88%.
Relative Value
Fair Zone
1399.65-3984.47
Current Price:1.74
99.88%
Undervalued
0.04
PE
1Y
3Y
5Y
Trailing
Forward
8.16
EV/EBITDA
CAMP4 Therapeutics Corp. (CAMP) has a current EV/EBITDA of 8.16. The 5-year average EV/EBITDA is 15.57. The thresholds are as follows: Strongly Undervalued below 6.05, Undervalued between 6.05 and 10.81, Fairly Valued between 20.32 and 10.81, Overvalued between 20.32 and 25.08, and Strongly Overvalued above 25.08. The current Forward EV/EBITDA of 8.16 falls within the Undervalued range.
47.19
EV/EBIT
CAMP4 Therapeutics Corp. (CAMP) has a current EV/EBIT of 47.19. The 5-year average EV/EBIT is 22.79. The thresholds are as follows: Strongly Undervalued below -93.32, Undervalued between -93.32 and -35.26, Fairly Valued between 80.84 and -35.26, Overvalued between 80.84 and 138.89, and Strongly Overvalued above 138.89. The current Forward EV/EBIT of 47.19 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
CAMP4 Therapeutics Corp. (CAMP) has a current PS of 0.00. The 5-year average PS is 0.63. The thresholds are as follows: Strongly Undervalued below -0.30, Undervalued between -0.30 and 0.17, Fairly Valued between 1.10 and 0.17, Overvalued between 1.10 and 1.57, and Strongly Overvalued above 1.57. The current Forward PS of 0.00 falls within the Undervalued range.
0.00
P/OCF
CAMP4 Therapeutics Corp. (CAMP) has a current P/OCF of 0.00. The 5-year average P/OCF is 5.29. The thresholds are as follows: Strongly Undervalued below -9.76, Undervalued between -9.76 and -2.23, Fairly Valued between 12.81 and -2.23, Overvalued between 12.81 and 20.34, and Strongly Overvalued above 20.34. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
CAMP4 Therapeutics Corp. (CAMP) has a current P/FCF of 0.00. The 5-year average P/FCF is -8.91. The thresholds are as follows: Strongly Undervalued below -80.28, Undervalued between -80.28 and -44.60, Fairly Valued between 26.77 and -44.60, Overvalued between 26.77 and 62.46, and Strongly Overvalued above 62.46. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
CAMP4 Therapeutics Corp (CAMP) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 3.70 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 3.78, the current P/B ratio is about -100.00% higher. CAMP4 Therapeutics Corp (CAMP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -123.78%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -62.00% , the current FCF yield is about -100.00% lower.
0.00
P/B
Median3y
3.70
Median5y
3.78
0.00
FCF Yield
Median3y
-123.78
Median5y
-62.00
Competitors Valuation Multiple
The average P/S ratio for CAMP's competitors is 1.18, providing a benchmark for relative valuation. CAMP4 Therapeutics Corp Corp (CAMP) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -98.79%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CAMP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CAMP in the past 1 year is driven by Unknown.
People Also Watch

BKHA
Black Hawk Acquisition Corp
10.990
USD
0.00%

ORMP
Oramed Pharmaceuticals Inc
2.160
USD
-2.26%

VOR
Vor Biopharma Inc
2.400
USD
-0.83%

MLSS
Milestone Scientific Inc
0.550
USD
+12.93%

CODA
Coda Octopus Group Inc
7.650
USD
0.00%

ASMB
Assembly Biosciences Inc
19.500
USD
0.00%

MODV
ModivCare Inc
2.975
USD
-3.41%

ALXO
ALX Oncology Holdings Inc
0.608
USD
-2.88%

SHIM
Shimmick Corp
2.050
USD
-0.97%

IROH
Iron Horse Acquisitions Corp
10.810
USD
-2.61%
FAQ

Is CAMP4 Therapeutics Corp (CAMP) currently overvalued or undervalued?
CAMP4 Therapeutics Corp (CAMP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 9.38. The fair price of CAMP4 Therapeutics Corp (CAMP) is between 1399.65 to 3984.47 according to relative valuation methord. Compared to the current price of 1.74 USD , CAMP4 Therapeutics Corp is Undervalued By 99.88% .

What is CAMP4 Therapeutics Corp (CAMP) fair value?

How does CAMP's valuation metrics compare to the industry average?

What is the current P/B ratio for CAMP4 Therapeutics Corp (CAMP) as of Jul 29 2025?

What is the current FCF Yield for CAMP4 Therapeutics Corp (CAMP) as of Jul 29 2025?

What is the current Forward P/E ratio for CAMP4 Therapeutics Corp (CAMP) as of Jul 29 2025?
